Exchange: NASDAQ·Updated 07:41 PM EDT

AMGN News

News
all
press releases
Amgen (AMGN) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.
Zacks
Amgen (AMGN) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.
Zacks
More News
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.
Zacks
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Amgen (AMGN) stood at $413.08, denoting a +2.6% move from the preceding trading day.
Zacks
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved Within three months of firing Tracy Beth H?eg, its top drug regulator, the FDA had approved the first mRNA flu shot, cleared a Sanofi diabetes treatment...
Zero Hedge
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Key PointsAmgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow...
Nasdaq News: Markets
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred on September 22,read more...
Benzinga
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
Zacks
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.
Zacks
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks

Advertisement|Remove ads.